A naturally occurring protein in the human body could protect people from one of the world's biggest killers—sepsis. The ...
A new study by researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain ...
Study represents a significant advancement in Grove’s Bionic Biologics™ platform – CHICAGO--(BUSINESS WIRE)--February 24, 2026-- Grove Biopharma, ...
VANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...
LOS ANGELES--(BUSINESS WIRE)--Laekna (2105.HK) announced today that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the ...
The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PH Lanifibranor was observed to decrease portal pressure by ...
Pancreatic malignancies remain some of the most challenging cancers to treat. Experts anticipate over 52,000 pancreatic cancer-related deaths this year. Sadly, the five-year survival rate for ...
New research shows that Rytvela, an anti-inflammatory drug candidate, decreased premature birth and infant mortality when ...
The hormone estrogen regulates binge drinking in females, causing them to “pregame” – consume large quantities of alcohol in the first 30 minutes after it’s offered, according to a preclinical study ...
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases ...
- Single-dose administration of LAE102 by IV or SC injection demonstrated a favorable safety profile in the healthy participants as well as robust and prolonged target engagement in the healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results